Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today released a white paper ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The Hims & Hers program offers a holistic, cost-effective, and personalized approach to reducing weight ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Hims & Hers and other telehealth providers say employers that balked at pricey brand-name shots are investigating cheaper off ...

Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions Hims & Hers Health, Inc. (“Hims & ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like ...

Hims&Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and improving profitability.